董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Webster | 男 | Independent Director | 64 | 20.89万美元 | 未持股 | 2025-08-07 |
| Andrew Allen | 男 | Director | 59 | 未披露 | 未持股 | 2025-08-07 |
| Nadim Ahmed | 男 | Director, President and Chief Executive Officer | 58 | 390.05万美元 | 未持股 | 2025-08-07 |
| Mittie Doyle | 女 | Director | 60 | 未披露 | 未持股 | 2025-08-07 |
| Mary T. Thistle | -- | Independent Director | -- | 未披露 | 未持股 | 2025-08-07 |
| David D. Meek | -- | Independent Director | -- | 未披露 | 未持股 | 2025-08-07 |
| Anthony Rosenberg | 男 | Chairman of the Board | 72 | 23.64万美元 | 未持股 | 2025-08-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer Michaelson | 女 | Chief Scientific Officer | 59 | 未披露 | 未持股 | 2025-08-07 |
| Corinne Savill | 女 | Chief Business Officer | 67 | 未披露 | 未持股 | 2025-08-07 |
| Nadim Ahmed | 男 | Director, President and Chief Executive Officer | 58 | 390.05万美元 | 未持股 | 2025-08-07 |
| Jeffrey Jones | 男 | Chief Medical Officer | 55 | 未披露 | 未持股 | 2025-08-07 |
| Jacquelyn Sumer, Esq | 女 | Chief Legal Officer, Chief Compliance Officer and Secretary | 48 | 未披露 | 未持股 | 2025-08-07 |
| Mary Kay Fenton | -- | Chief Financial Officer and Principal Accounting Officer | -- | 未披露 | 未持股 | 2025-08-07 |
董事简历
中英对照 | 中文 | 英文- Stephen Webster
-
Stephen Webster自2020年9月以来一直担任我们的董事会成员。韦伯斯特先生从2014年7月起担任星火治疗公司的首席财务官，直到2019年12月该公司被罗氏控股（Roche Holding AG）以48亿美元收购。他此前曾担任Optimer Pharmaceuticals公司的高级副总裁兼首席财务官（从2012年7月到2013年10月被Cubist Pharmaceuticals公司收购）。Webster先生目前在NextCure，Inc.公司董事会任职。纳斯达克市场代码:NXTC，Nabriva Therapeutics AG（原Nabriva Therapeutics plc）（纳斯达克市场代码:NBRV）和TCR2（纳斯达克市场代码:TCRR）。Webster先生在达特茅斯学院（Dartmouth College）获得经济学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得金融学工商管理硕士学位。
Stephen Webster,Mr. Webster has served as a member of Cullinan Oncology, Inc. board of directors since September 2020. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, Inc., a gene therapy company, from July 2014 until its acquisition by Roche Holding AG for $4.8 billion in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals Inc. from July 2012 until its acquisition by Cubist Pharmaceuticals Inc. in October 2013. Mr. Webster currently serves on the board of directors of NextCure, Inc., Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) and TCR2. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania. - Stephen Webster自2020年9月以来一直担任我们的董事会成员。韦伯斯特先生从2014年7月起担任星火治疗公司的首席财务官，直到2019年12月该公司被罗氏控股（Roche Holding AG）以48亿美元收购。他此前曾担任Optimer Pharmaceuticals公司的高级副总裁兼首席财务官（从2012年7月到2013年10月被Cubist Pharmaceuticals公司收购）。Webster先生目前在NextCure，Inc.公司董事会任职。纳斯达克市场代码:NXTC，Nabriva Therapeutics AG（原Nabriva Therapeutics plc）（纳斯达克市场代码:NBRV）和TCR2（纳斯达克市场代码:TCRR）。Webster先生在达特茅斯学院（Dartmouth College）获得经济学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得金融学工商管理硕士学位。
- Stephen Webster,Mr. Webster has served as a member of Cullinan Oncology, Inc. board of directors since September 2020. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, Inc., a gene therapy company, from July 2014 until its acquisition by Roche Holding AG for $4.8 billion in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals Inc. from July 2012 until its acquisition by Cubist Pharmaceuticals Inc. in October 2013. Mr. Webster currently serves on the board of directors of NextCure, Inc., Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) and TCR2. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.
- Andrew Allen
-
Andrew Allen于2018年12月加入我们的董事会。艾伦博士是GritstoneOncology，Inc.的联合创始人，自2015年8月起担任其总裁兼首席执行官。2009年4月至2015年7月，Allen博士共同创立了ClovisOncology，Inc.，该公司是一家公共医药开发公司，并担任其临床和临床前开发执行Vice President兼首席医疗官。此前，他曾担任Pharmion Corporation的首席医疗官（从2006年到2008年）。此前，艾伦博士曾在Chiron Corporation和雅培公司担任临床开发领导职务，并在麦肯锡公司（McKinsey&Company）工作，在那里他为生命科学公司提供战略问题方面的建议。他目前任职于GritstoneOncology，Inc.、Epizyme，Inc.、SierraOncology，Inc.和Revisope Oncology，Inc.的董事会。艾伦博士曾于2015年11月至2017年12月被吉利德科学公司收购期间担任私营生物技术公司Cell Design Labs的董事会成员。Allen博士在牛津大学（Oxford University）获得医学资格，并在伦敦帝国理工学院（Imperial College of Science，Technology and Medicine）获得免疫学博士学位。
Andrew Allen joined Tcr2 Therapeutics Inc. Board of Directors in December 2018. Dr. Allen is a co-founder of Gritstone Oncology, Inc., and has served as its President and Chief Executive Officer since August 2015. Dr. Allen previously co-founded Clovis Oncology, Inc., a public pharmaceutical development company, and served as its executive vice president of clinical and preclinical development and chief medical officer from April 2009 to July 2015. Prior to that, he was chief medical officer at Pharmion Corporation from 2006 to 2008. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Gritstone Oncology, Inc., Sierra Oncology, Inc., Revitope Oncology, Inc. and Verge Genomics, Inc. Dr. Allen previously served on the board of directors for Epizyme, Inc. from 2014 until 2021 and Cell Design Labs, a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London. - Andrew Allen于2018年12月加入我们的董事会。艾伦博士是GritstoneOncology，Inc.的联合创始人，自2015年8月起担任其总裁兼首席执行官。2009年4月至2015年7月，Allen博士共同创立了ClovisOncology，Inc.，该公司是一家公共医药开发公司，并担任其临床和临床前开发执行Vice President兼首席医疗官。此前，他曾担任Pharmion Corporation的首席医疗官（从2006年到2008年）。此前，艾伦博士曾在Chiron Corporation和雅培公司担任临床开发领导职务，并在麦肯锡公司（McKinsey&Company）工作，在那里他为生命科学公司提供战略问题方面的建议。他目前任职于GritstoneOncology，Inc.、Epizyme，Inc.、SierraOncology，Inc.和Revisope Oncology，Inc.的董事会。艾伦博士曾于2015年11月至2017年12月被吉利德科学公司收购期间担任私营生物技术公司Cell Design Labs的董事会成员。Allen博士在牛津大学（Oxford University）获得医学资格，并在伦敦帝国理工学院（Imperial College of Science，Technology and Medicine）获得免疫学博士学位。
- Andrew Allen joined Tcr2 Therapeutics Inc. Board of Directors in December 2018. Dr. Allen is a co-founder of Gritstone Oncology, Inc., and has served as its President and Chief Executive Officer since August 2015. Dr. Allen previously co-founded Clovis Oncology, Inc., a public pharmaceutical development company, and served as its executive vice president of clinical and preclinical development and chief medical officer from April 2009 to July 2015. Prior to that, he was chief medical officer at Pharmion Corporation from 2006 to 2008. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Gritstone Oncology, Inc., Sierra Oncology, Inc., Revitope Oncology, Inc. and Verge Genomics, Inc. Dr. Allen previously served on the board of directors for Epizyme, Inc. from 2014 until 2021 and Cell Design Labs, a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London.
- Nadim Ahmed
-
Nadim Ahmed自2021年10月起，Ahmed一直担任Cullinan Oncology，Inc.股份有限公司总裁兼首席执行官，以及Cullinam Oncologry，Inc.股份有限公司董事会成员。加入公司之前，Ahmed先生于2019年11月至2021年1月担任百时美施贵宝（“BMS”）血液科总裁。在此之前，他于2010年3月至2019年11月在Celgene Corporation（“Celgene”）担任越来越重要的职务，最近担任全球血液学和肿瘤学总裁。在担任Celgene之前，Ahmed先生于1998年6月至2010年3月在葛兰素史克有限公司（“葛兰素史科”）担任越来越多的职责，最近一次担任血液肿瘤特许经营高级营销总监。Ahmed先生拥有Loughborough University的理学硕士学位和University College London的理学学士学位。
Nadim Ahmed,Mr. Ahmed has served as Cullinan Oncology, Inc. President and Chief Executive Officer and member of Cullinan Oncology, Inc. board of directors since October 2021. Before joining the Company, Mr. Ahmed served as President, Hematology at Bristol Myers Squibb ("BMS"), from November 2019 through January 2021. Prior to this, he served in increasing roles of responsibility at Celgene Corporation ("Celgene") from March 2010 to November 2019, most recently as the President, Global Hematology & Oncology. Prior to his tenure at Celgene, Mr. Ahmed served in increasing roles of responsibility at GlaxoSmithKline plc ("GlaxoSmithKline") from June 1998 through March 2010, most recently as the Senior Marketing Director, Hematologic Oncology Franchise. Mr. Ahmed holds a Master of Science degree from Loughborough University and a Bachelor of Science degree from University College London. - Nadim Ahmed自2021年10月起，Ahmed一直担任Cullinan Oncology，Inc.股份有限公司总裁兼首席执行官，以及Cullinam Oncologry，Inc.股份有限公司董事会成员。加入公司之前，Ahmed先生于2019年11月至2021年1月担任百时美施贵宝（“BMS”）血液科总裁。在此之前，他于2010年3月至2019年11月在Celgene Corporation（“Celgene”）担任越来越重要的职务，最近担任全球血液学和肿瘤学总裁。在担任Celgene之前，Ahmed先生于1998年6月至2010年3月在葛兰素史克有限公司（“葛兰素史科”）担任越来越多的职责，最近一次担任血液肿瘤特许经营高级营销总监。Ahmed先生拥有Loughborough University的理学硕士学位和University College London的理学学士学位。
- Nadim Ahmed,Mr. Ahmed has served as Cullinan Oncology, Inc. President and Chief Executive Officer and member of Cullinan Oncology, Inc. board of directors since October 2021. Before joining the Company, Mr. Ahmed served as President, Hematology at Bristol Myers Squibb ("BMS"), from November 2019 through January 2021. Prior to this, he served in increasing roles of responsibility at Celgene Corporation ("Celgene") from March 2010 to November 2019, most recently as the President, Global Hematology & Oncology. Prior to his tenure at Celgene, Mr. Ahmed served in increasing roles of responsibility at GlaxoSmithKline plc ("GlaxoSmithKline") from June 1998 through March 2010, most recently as the Senior Marketing Director, Hematologic Oncology Franchise. Mr. Ahmed holds a Master of Science degree from Loughborough University and a Bachelor of Science degree from University College London.
- Mittie Doyle
-
Mittie Doyle，自2024年7月起担任上市生物技术公司Avalo Therapeutics, Inc.的首席医疗官。2021年9月至2024年7月，Doyle博士在私营生物技术公司Aro Biotherapeutics担任首席医疗官。在此之前，她于2017年10月至2021年9月在全球生物技术公司CSL Behring担任免疫学副总裁、全球治疗领域负责人。在任职于CSL Behring之前，Doyle博士曾于2016年8月至2017年10月在Shire Pharmaceuticals担任副总裁兼全球开发负责人，于2015年4月至2016年7月在Flexion Therapeutics担任临床研究副总裁等高级职务。Doyle博士目前在一家私营公司的董事会任职，此前曾在2022年3月至2023年8月期间在上市公司DICE Therapeutics（“DICE”）的董事会任职，当时DICE被礼来公司收购。Doyle博士获得了普林斯顿大学的学士学位和耶鲁大学医学院的医学博士学位。她在哈佛医学院完成了博士后培训，包括在麻省总医院的内科住院医师实习，以及在布莱根妇女医院的风湿病学和免疫学临床/研究奖学金。
Mittie Doyle has served as Avalo's Chief Medical Officer since July 2024. She most recently served as Chief Medical Officer at Aro Biotherapeutics, Co., a biotechnology company specializing in tissue targeted genetic medicines, from September 2021 to July 2024. Prior to that, she served as Vice President, Global Therapeutic Area Head, Immunology at CSL Behring, a global biotech company, from October 2017 to October 2021. Prior to her time at CSL Behring, Dr. Doyle held senior level roles as Vice President, Global Development Lead at Shire Pharmaceuticals, plc beten Augt 2016 to October 2017, Vice President, Clinical Research, Flexion Therapeutics, Inc., beten April 2015 to Augt 2016 and Senior Medical Director at Alexion Pharmaceuticals, Inc. (previoly, Nasdaq: ALXN) beten June 2012 to April 2021. Dr. Doyle currently serves on the Board of Directors of Santa Ana Bio, Inc., a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases. Previoly, Dr. Doyle served on the board of directors of DICE Therapeutics, Inc. ("DICE"), a former public company, from March 2022 until DICE was acquired by Eli Lilly and Company in Augt 2023. During her career, Dr. Doyle has advanced assets across a broad range of immune mediated and orphan diseases and has led teams with responsibilities for design and execution of first in human through Phase 2 and 3 trials, resulting in several global regulatory approvals. Dr. Doyle received her B.A. magna cum laude from Princeton University in Romance Languages and her M.D. cum laude from Yale Medical School. She completed her postdoctoral training at Harvard Medical School including residency in Internal Medicine at Massachetts General Hospital and clinical/research fellowship in Rheumatology and Immunology at Brigham and Women's Hospital. - Mittie Doyle，自2024年7月起担任上市生物技术公司Avalo Therapeutics, Inc.的首席医疗官。2021年9月至2024年7月，Doyle博士在私营生物技术公司Aro Biotherapeutics担任首席医疗官。在此之前，她于2017年10月至2021年9月在全球生物技术公司CSL Behring担任免疫学副总裁、全球治疗领域负责人。在任职于CSL Behring之前，Doyle博士曾于2016年8月至2017年10月在Shire Pharmaceuticals担任副总裁兼全球开发负责人，于2015年4月至2016年7月在Flexion Therapeutics担任临床研究副总裁等高级职务。Doyle博士目前在一家私营公司的董事会任职，此前曾在2022年3月至2023年8月期间在上市公司DICE Therapeutics（“DICE”）的董事会任职，当时DICE被礼来公司收购。Doyle博士获得了普林斯顿大学的学士学位和耶鲁大学医学院的医学博士学位。她在哈佛医学院完成了博士后培训，包括在麻省总医院的内科住院医师实习，以及在布莱根妇女医院的风湿病学和免疫学临床/研究奖学金。
- Mittie Doyle has served as Avalo's Chief Medical Officer since July 2024. She most recently served as Chief Medical Officer at Aro Biotherapeutics, Co., a biotechnology company specializing in tissue targeted genetic medicines, from September 2021 to July 2024. Prior to that, she served as Vice President, Global Therapeutic Area Head, Immunology at CSL Behring, a global biotech company, from October 2017 to October 2021. Prior to her time at CSL Behring, Dr. Doyle held senior level roles as Vice President, Global Development Lead at Shire Pharmaceuticals, plc beten Augt 2016 to October 2017, Vice President, Clinical Research, Flexion Therapeutics, Inc., beten April 2015 to Augt 2016 and Senior Medical Director at Alexion Pharmaceuticals, Inc. (previoly, Nasdaq: ALXN) beten June 2012 to April 2021. Dr. Doyle currently serves on the Board of Directors of Santa Ana Bio, Inc., a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases. Previoly, Dr. Doyle served on the board of directors of DICE Therapeutics, Inc. ("DICE"), a former public company, from March 2022 until DICE was acquired by Eli Lilly and Company in Augt 2023. During her career, Dr. Doyle has advanced assets across a broad range of immune mediated and orphan diseases and has led teams with responsibilities for design and execution of first in human through Phase 2 and 3 trials, resulting in several global regulatory approvals. Dr. Doyle received her B.A. magna cum laude from Princeton University in Romance Languages and her M.D. cum laude from Yale Medical School. She completed her postdoctoral training at Harvard Medical School including residency in Internal Medicine at Massachetts General Hospital and clinical/research fellowship in Rheumatology and Immunology at Brigham and Women's Hospital.
- Mary T. Thistle
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- David D. Meek
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Anthony Rosenberg
-
Anthony Rosenberg，自2017年8月起担任Cullinan Oncology，Inc.董事会成员，自2020年4月起担任Cullinan Oncology，Inc.董事会主席。目前，Rosenberg先生担任TR Advisory Services GmbH的首席执行官，这是一家就业务发展、许可和并购提供咨询的咨询公司。从2015年4月至2020年4月，Rosenberg先生担任MPM的董事总经理。2012年1月至2015年2月，Rosenberg先生在诺华担任并购和许可公司负责人。Rosenberg先生目前在argenx SE的董事会任职。此前，Rosenberg先生曾在Radius Health, Inc.的董事会任职。他还在两家私营公司的董事会任职。Rosenberg先生拥有莱斯特大学的理学学士学位和理学硕士学位。伦敦大学生理学。
Anthony Rosenberg,has served as a member of Cullinan Oncology, Inc. board of directors since August 2017 and as the Chairperson of Cullinan Oncology, Inc. board of directors since April 2020. Currently, Mr. Rosenberg serves as the Chief Executive Officer of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing, and mergers and acquisitions. From April 2015 to April 2020, Mr. Rosenberg served as a Managing Director of MPM. From January 2012 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis. Mr. Rosenberg currently serves on the board of directors of argenx SE. Previously, Mr. Rosenberg served on the board of directors of Radius Health, Inc. He also serves on the board of two private companies. Mr. Rosenberg holds a B.Sc. from the University of Leicester and a M.Sc. Physiology from the University of London. - Anthony Rosenberg，自2017年8月起担任Cullinan Oncology，Inc.董事会成员，自2020年4月起担任Cullinan Oncology，Inc.董事会主席。目前，Rosenberg先生担任TR Advisory Services GmbH的首席执行官，这是一家就业务发展、许可和并购提供咨询的咨询公司。从2015年4月至2020年4月，Rosenberg先生担任MPM的董事总经理。2012年1月至2015年2月，Rosenberg先生在诺华担任并购和许可公司负责人。Rosenberg先生目前在argenx SE的董事会任职。此前，Rosenberg先生曾在Radius Health, Inc.的董事会任职。他还在两家私营公司的董事会任职。Rosenberg先生拥有莱斯特大学的理学学士学位和理学硕士学位。伦敦大学生理学。
- Anthony Rosenberg,has served as a member of Cullinan Oncology, Inc. board of directors since August 2017 and as the Chairperson of Cullinan Oncology, Inc. board of directors since April 2020. Currently, Mr. Rosenberg serves as the Chief Executive Officer of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing, and mergers and acquisitions. From April 2015 to April 2020, Mr. Rosenberg served as a Managing Director of MPM. From January 2012 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis. Mr. Rosenberg currently serves on the board of directors of argenx SE. Previously, Mr. Rosenberg served on the board of directors of Radius Health, Inc. He also serves on the board of two private companies. Mr. Rosenberg holds a B.Sc. from the University of Leicester and a M.Sc. Physiology from the University of London.
高管简历
中英对照 | 中文 | 英文- Jennifer Michaelson
Jennifer Michaelson自2018年1月起在公司担任越来越多的职责，最近一次是自2020年1月起担任生物制剂首席开发官，此前曾于2018年1月至2019年12月担任临床前研究和早期开发Vice President。加入公司之前，Michaelson博士于2017年7月至2017年12月担任Celsius Therapeutics，Inc.的生物制剂主管。在此之前，她于2012年9月至2017年7月在JounceTherapeutics，Inc.担任越来越重要的职务，最近担任高级总监兼执行项目负责人，此前曾担任肿瘤免疫学总监兼顾问。此前，在Biogen Idec Inc.的10年任期内，Michaelson博士担任肿瘤学和免疫学治疗领域的几个单克隆抗体和双特异性抗体项目的项目负责人。Michaelson博士拥有普林斯顿大学（Princeton University）生物学学士学位和阿尔伯特爱因斯坦医学院（Albert Einstein College of Medicine）细胞生物系博士学位，并完成了哈佛医学院（Harvard Medical School）遗传学系Philip Leder’；s实验室的博士后奖学金。
Jennifer Michaelson,Ph.D. Dr. Michaelson has served as Cullinan Oncology, Inc. Chief Development Officer since February 2022. Previously, she was Chief Development Officer, Biologics of the Company from January 2020 to February 2022 and Vice President, Preclinical Research and Early Development of the Company from January 2018 through December 2019. Before joining the Company, Dr. Michaelson served as the Head of Biologics at Celsius Therapeutics, Inc., a biotechnology company, from July 2017 through December 2017. Prior to this, she served in increasing roles of responsibility at Jounce Therapeutics, Inc., from September 2012 through July 2017, most recently as Senior Director and Executive Program Leader and previously as Director of Tumor Immunology and as a consultant. Previously, during her 10 year tenure at Biogen Idec Inc., Dr. Michaelson served as project leader for several monoclonal antibody and bispecific antibody programs in both the oncology and immunology therapeutic areas. Dr. Michaelson holds a B.A. in Biology from Princeton University and Ph.D. from the Department of Cell Biology at Albert Einstein College of Medicine, and completed a post-doctoral fellowship in Philip Leder's laboratory in the Department of Genetics at Harvard Medical School.- Jennifer Michaelson自2018年1月起在公司担任越来越多的职责，最近一次是自2020年1月起担任生物制剂首席开发官，此前曾于2018年1月至2019年12月担任临床前研究和早期开发Vice President。加入公司之前，Michaelson博士于2017年7月至2017年12月担任Celsius Therapeutics，Inc.的生物制剂主管。在此之前，她于2012年9月至2017年7月在JounceTherapeutics，Inc.担任越来越重要的职务，最近担任高级总监兼执行项目负责人，此前曾担任肿瘤免疫学总监兼顾问。此前，在Biogen Idec Inc.的10年任期内，Michaelson博士担任肿瘤学和免疫学治疗领域的几个单克隆抗体和双特异性抗体项目的项目负责人。Michaelson博士拥有普林斯顿大学（Princeton University）生物学学士学位和阿尔伯特爱因斯坦医学院（Albert Einstein College of Medicine）细胞生物系博士学位，并完成了哈佛医学院（Harvard Medical School）遗传学系Philip Leder’；s实验室的博士后奖学金。
- Jennifer Michaelson,Ph.D. Dr. Michaelson has served as Cullinan Oncology, Inc. Chief Development Officer since February 2022. Previously, she was Chief Development Officer, Biologics of the Company from January 2020 to February 2022 and Vice President, Preclinical Research and Early Development of the Company from January 2018 through December 2019. Before joining the Company, Dr. Michaelson served as the Head of Biologics at Celsius Therapeutics, Inc., a biotechnology company, from July 2017 through December 2017. Prior to this, she served in increasing roles of responsibility at Jounce Therapeutics, Inc., from September 2012 through July 2017, most recently as Senior Director and Executive Program Leader and previously as Director of Tumor Immunology and as a consultant. Previously, during her 10 year tenure at Biogen Idec Inc., Dr. Michaelson served as project leader for several monoclonal antibody and bispecific antibody programs in both the oncology and immunology therapeutic areas. Dr. Michaelson holds a B.A. in Biology from Princeton University and Ph.D. from the Department of Cell Biology at Albert Einstein College of Medicine, and completed a post-doctoral fellowship in Philip Leder's laboratory in the Department of Genetics at Harvard Medical School.
- Corinne Savill
Corinne Savill自2017年2月起担任我们的代理首席商务官。在加入公司之前，Savill博士在Novartis Pharma AG担任越来越多的职责，包括从2013年6月至2017年2月担任业务开发和许可全球主管，从2010年9月至2013年6月担任定价和市场准入全球主管搜索和评估，从2005年1月到2010年8月担任业务开发和许可，从2002年8月到2005年1月担任移植和免疫学业务单元欧洲区域经理。任职Novartis公司之前，Savill曾担任Imutran公司（英国生物技术公司，被Novartis公司收购）的首席执行官。她此前也曾任职AstraZeneca公司的研究。Savill博士拥有英国曼彻斯特大学（University of Manchester UK）生物化学学士学位，并在University College and Middlesex School of Medicine（Ph.D.）和伦敦Charing Cross Sunley Research Centre进行研究生研究。
Corinne Savill,Ph.D. Dr. Savill has served as Cullinan Oncology, Inc. Chief Business Officer since February 2017. Before joining the Company, Dr. Savill served in increasing roles of responsibility at Novartis Pharma AG ("Novartis"), including Global Head of Business Development and Licensing from June 2013 through February 2017, Global Head of Pricing and Market Access from September 2010 through June 2013, Global Head Search and Evaluation, Business Development and Licensing from January 2005 through August 2010 and Regional Manager Europe, Transplantation and Immunology Business Unit from August 2002 through Jan 2005. Prior to her tenure at Novartis, Dr. Savill was Chief Executive Officer of Imutran, a UK based biotechnology company, which was acquired by Novartis. She also previously worked in research at AstraZeneca. Dr. Savill holds a B.S. in Biochemistry from the University of Manchester and obtained her Ph.D. at University College and Middlesex School of Medicine and the Charing Cross Sunley Research Centre in London.- Corinne Savill自2017年2月起担任我们的代理首席商务官。在加入公司之前，Savill博士在Novartis Pharma AG担任越来越多的职责，包括从2013年6月至2017年2月担任业务开发和许可全球主管，从2010年9月至2013年6月担任定价和市场准入全球主管搜索和评估，从2005年1月到2010年8月担任业务开发和许可，从2002年8月到2005年1月担任移植和免疫学业务单元欧洲区域经理。任职Novartis公司之前，Savill曾担任Imutran公司（英国生物技术公司，被Novartis公司收购）的首席执行官。她此前也曾任职AstraZeneca公司的研究。Savill博士拥有英国曼彻斯特大学（University of Manchester UK）生物化学学士学位，并在University College and Middlesex School of Medicine（Ph.D.）和伦敦Charing Cross Sunley Research Centre进行研究生研究。
- Corinne Savill,Ph.D. Dr. Savill has served as Cullinan Oncology, Inc. Chief Business Officer since February 2017. Before joining the Company, Dr. Savill served in increasing roles of responsibility at Novartis Pharma AG ("Novartis"), including Global Head of Business Development and Licensing from June 2013 through February 2017, Global Head of Pricing and Market Access from September 2010 through June 2013, Global Head Search and Evaluation, Business Development and Licensing from January 2005 through August 2010 and Regional Manager Europe, Transplantation and Immunology Business Unit from August 2002 through Jan 2005. Prior to her tenure at Novartis, Dr. Savill was Chief Executive Officer of Imutran, a UK based biotechnology company, which was acquired by Novartis. She also previously worked in research at AstraZeneca. Dr. Savill holds a B.S. in Biochemistry from the University of Manchester and obtained her Ph.D. at University College and Middlesex School of Medicine and the Charing Cross Sunley Research Centre in London.
- Nadim Ahmed
Nadim Ahmed自2021年10月起，Ahmed一直担任Cullinan Oncology，Inc.股份有限公司总裁兼首席执行官，以及Cullinam Oncologry，Inc.股份有限公司董事会成员。加入公司之前，Ahmed先生于2019年11月至2021年1月担任百时美施贵宝（“BMS”）血液科总裁。在此之前，他于2010年3月至2019年11月在Celgene Corporation（“Celgene”）担任越来越重要的职务，最近担任全球血液学和肿瘤学总裁。在担任Celgene之前，Ahmed先生于1998年6月至2010年3月在葛兰素史克有限公司（“葛兰素史科”）担任越来越多的职责，最近一次担任血液肿瘤特许经营高级营销总监。Ahmed先生拥有Loughborough University的理学硕士学位和University College London的理学学士学位。
Nadim Ahmed,Mr. Ahmed has served as Cullinan Oncology, Inc. President and Chief Executive Officer and member of Cullinan Oncology, Inc. board of directors since October 2021. Before joining the Company, Mr. Ahmed served as President, Hematology at Bristol Myers Squibb ("BMS"), from November 2019 through January 2021. Prior to this, he served in increasing roles of responsibility at Celgene Corporation ("Celgene") from March 2010 to November 2019, most recently as the President, Global Hematology & Oncology. Prior to his tenure at Celgene, Mr. Ahmed served in increasing roles of responsibility at GlaxoSmithKline plc ("GlaxoSmithKline") from June 1998 through March 2010, most recently as the Senior Marketing Director, Hematologic Oncology Franchise. Mr. Ahmed holds a Master of Science degree from Loughborough University and a Bachelor of Science degree from University College London.- Nadim Ahmed自2021年10月起，Ahmed一直担任Cullinan Oncology，Inc.股份有限公司总裁兼首席执行官，以及Cullinam Oncologry，Inc.股份有限公司董事会成员。加入公司之前，Ahmed先生于2019年11月至2021年1月担任百时美施贵宝（“BMS”）血液科总裁。在此之前，他于2010年3月至2019年11月在Celgene Corporation（“Celgene”）担任越来越重要的职务，最近担任全球血液学和肿瘤学总裁。在担任Celgene之前，Ahmed先生于1998年6月至2010年3月在葛兰素史克有限公司（“葛兰素史科”）担任越来越多的职责，最近一次担任血液肿瘤特许经营高级营销总监。Ahmed先生拥有Loughborough University的理学硕士学位和University College London的理学学士学位。
- Nadim Ahmed,Mr. Ahmed has served as Cullinan Oncology, Inc. President and Chief Executive Officer and member of Cullinan Oncology, Inc. board of directors since October 2021. Before joining the Company, Mr. Ahmed served as President, Hematology at Bristol Myers Squibb ("BMS"), from November 2019 through January 2021. Prior to this, he served in increasing roles of responsibility at Celgene Corporation ("Celgene") from March 2010 to November 2019, most recently as the President, Global Hematology & Oncology. Prior to his tenure at Celgene, Mr. Ahmed served in increasing roles of responsibility at GlaxoSmithKline plc ("GlaxoSmithKline") from June 1998 through March 2010, most recently as the Senior Marketing Director, Hematologic Oncology Franchise. Mr. Ahmed holds a Master of Science degree from Loughborough University and a Bachelor of Science degree from University College London.
- Jeffrey Jones
Jeffrey Jones医学博士琼斯博士自2022年2月起担任Cullinan Oncology, Inc.首席医疗官。在加入公司之前，琼斯博士于2020年4月至2022年2月担任BMS全球药物开发、淋巴瘤和骨髓病副总裁，并于2017年8月至2020年4月担任BMS全球临床研发执行医疗总监。在此之前，琼斯博士曾担任俄亥俄州立大学医学院临床内科副教授。在此之前，琼斯博士曾于2006年至2014年在俄亥俄州立大学担任临床指导。琼斯博士在密歇根州安娜堡的密歇根大学医学院获得了医学博士学位，并在蒙特利尔的麦吉尔大学医学院完成了内科住院医师实习，并在德克萨斯州休斯顿的MD安德森癌症中心获得了血液学和医学肿瘤学研究金。琼斯博士还拥有俄亥俄州立大学费舍尔商学院的工商管理硕士学位和德克萨斯大学公共卫生学院的公共卫生硕士学位。
Jeffrey Jones,M.D. Dr. Jones has served as Cullinan Oncology, Inc. Chief Medical Officer since February 2022. Before joining the Company, Dr. Jones served as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases at BMS from April 2020 to February 2022 and as Executive Medical Director, Global Clinical Research and Development at BMS from August 2017 to April 2020. Prior to this, Dr. Jones served as Associate Professor of Clinical Internal Medicine at The Ohio State University College of Medicine. Prior to that, Dr. Jones served as a Clinical Instructor from 2006 to 2014 at The Ohio State University. Dr. Jones received his M.D. from University of Michigan Medical School in Ann Arbor, Michigan and completed his residency in internal medicine at McGill University Faculty of Medicine in Montreal and a fellowship in hematology and medical oncology at MD Anderson Cancer Center in Houston, Texas. Dr. Jones also holds an M.B.A. from The Ohio State University Fisher College of Business and an M.P.H. from the University of Texas School of Public Health.- Jeffrey Jones医学博士琼斯博士自2022年2月起担任Cullinan Oncology, Inc.首席医疗官。在加入公司之前，琼斯博士于2020年4月至2022年2月担任BMS全球药物开发、淋巴瘤和骨髓病副总裁，并于2017年8月至2020年4月担任BMS全球临床研发执行医疗总监。在此之前，琼斯博士曾担任俄亥俄州立大学医学院临床内科副教授。在此之前，琼斯博士曾于2006年至2014年在俄亥俄州立大学担任临床指导。琼斯博士在密歇根州安娜堡的密歇根大学医学院获得了医学博士学位，并在蒙特利尔的麦吉尔大学医学院完成了内科住院医师实习，并在德克萨斯州休斯顿的MD安德森癌症中心获得了血液学和医学肿瘤学研究金。琼斯博士还拥有俄亥俄州立大学费舍尔商学院的工商管理硕士学位和德克萨斯大学公共卫生学院的公共卫生硕士学位。
- Jeffrey Jones,M.D. Dr. Jones has served as Cullinan Oncology, Inc. Chief Medical Officer since February 2022. Before joining the Company, Dr. Jones served as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases at BMS from April 2020 to February 2022 and as Executive Medical Director, Global Clinical Research and Development at BMS from August 2017 to April 2020. Prior to this, Dr. Jones served as Associate Professor of Clinical Internal Medicine at The Ohio State University College of Medicine. Prior to that, Dr. Jones served as a Clinical Instructor from 2006 to 2014 at The Ohio State University. Dr. Jones received his M.D. from University of Michigan Medical School in Ann Arbor, Michigan and completed his residency in internal medicine at McGill University Faculty of Medicine in Montreal and a fellowship in hematology and medical oncology at MD Anderson Cancer Center in Houston, Texas. Dr. Jones also holds an M.B.A. from The Ohio State University Fisher College of Business and an M.P.H. from the University of Texas School of Public Health.
- Jacquelyn Sumer, Esq
Jacquelyn Sumer，Esq，Esq。Sumer女士自2022年8月起担任Cullinan Oncology, Inc.首席法务官。在加入公司之前，Sumer女士于2021年2月至2022年6月担任Genocea Biosciences, Inc.（Genocea Biosciences，Inc.）的首席法律和合规官。在Genocea之前，Sumer女士于2019年11月至2021年2月担任房舍管理处副总裁兼助理总法律顾问。在此之前，她曾于2018年7月至2019年11月担任Celgene的CAR T法律团队负责人。她曾在Kaye Scholer，LLP工作，并在华盛顿特区的美国地区法院为Gladys Kessler阁下担任书记员。Sumer女士拥有杜克大学法学院国际法和比较法的法学博士和法学硕士学位，以及巴克内尔大学的学士学位。
Jacquelyn Sumer, Esq,Esq. Ms. Sumer has served as Cullinan Oncology, Inc. Chief Legal Officer since August 2022. Before joining the Company, Ms. Sumer served as Chief Legal and Compliance Officer at Genocea Biosciences, Inc. ("Genocea") from February 2021 to June 2022. Prior to Genocea, Ms. Sumer was Vice President, Assistant General Counsel at BMS from November 2019 to February 2021. Prior to this, she served as head of Celgene's CAR T legal team from July 2018 to November 2019. She previously worked at Kaye Scholer, LLP and clerked for the Honorable Gladys Kessler at the United States District Court in Washington D.C. Ms. Sumer holds a J.D. and a Master of Laws in international and comparative law from Duke University School of Law and a B.A. from Bucknell University.- Jacquelyn Sumer，Esq，Esq。Sumer女士自2022年8月起担任Cullinan Oncology, Inc.首席法务官。在加入公司之前，Sumer女士于2021年2月至2022年6月担任Genocea Biosciences, Inc.（Genocea Biosciences，Inc.）的首席法律和合规官。在Genocea之前，Sumer女士于2019年11月至2021年2月担任房舍管理处副总裁兼助理总法律顾问。在此之前，她曾于2018年7月至2019年11月担任Celgene的CAR T法律团队负责人。她曾在Kaye Scholer，LLP工作，并在华盛顿特区的美国地区法院为Gladys Kessler阁下担任书记员。Sumer女士拥有杜克大学法学院国际法和比较法的法学博士和法学硕士学位，以及巴克内尔大学的学士学位。
- Jacquelyn Sumer, Esq,Esq. Ms. Sumer has served as Cullinan Oncology, Inc. Chief Legal Officer since August 2022. Before joining the Company, Ms. Sumer served as Chief Legal and Compliance Officer at Genocea Biosciences, Inc. ("Genocea") from February 2021 to June 2022. Prior to Genocea, Ms. Sumer was Vice President, Assistant General Counsel at BMS from November 2019 to February 2021. Prior to this, she served as head of Celgene's CAR T legal team from July 2018 to November 2019. She previously worked at Kaye Scholer, LLP and clerked for the Honorable Gladys Kessler at the United States District Court in Washington D.C. Ms. Sumer holds a J.D. and a Master of Laws in international and comparative law from Duke University School of Law and a B.A. from Bucknell University.
- Mary Kay Fenton
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介